Eversept Partners’s Cymabay Therapeutics CBAY Stock Holding History

Eversept Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-84,296	Closed	-$604K	–	66
2019 Q2	$604K	Sell	84,296 -23,000	-21%	-$260K	0.17%	54
2019 Q1	$1.42M	Buy	107,296 +60,200	+128%	+$640K	0.42%	36
2018 Q4	$371K	Sell	47,096 -25,000	-35%	-$238K	0.2%	47
2018 Q3	$799K	Sell	72,096 -35,000	-33%	-$435K	0.35%	40
2018 Q2	$1.44M	Buy	+107,096	New	+$1.34M	0.66%	31

Other funds holding CBAY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Eversept Partners's CBAY Position: Q3 2019 in Review

Eversept Partners sold out of Cymabay Therapeutics (CBAY) in Q3 2019, closing a stake of 84,296 shares — an estimated $604K sold.

Eversept Partners first reported a position in CBAY in Q2 2018 and held it in 5 quarters. The position peaked at $1.44M in Q2 2018. 137 funds tracked by Wall St. Rank hold CBAY as of Q3 2019.

Eversept Partners reported no remaining Cymabay Therapeutics position as of Q3 2019 after selling out during the quarter.
Eversept Partners sold 84,296 Cymabay Therapeutics shares in Q3 2019, an estimated $604K.
Eversept Partners first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 5 quarters.
Eversept Partners's Cymabay Therapeutics position peaked at $1.44M in Q2 2018.
137 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2019.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.